resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors
“Jeffrey’s extensive experience with clinical and pipeline development, including the fields of respiratory and infectious diseases, makes him a highly valuable addition to our Board of Directors,” said
Dr. Chodakewitz has decades of experience holding leadership positions in world class drug development organizations. He currently serves as Executive Vice President, Clinical Medicine and External Innovation, at
“I am thrilled to join resTORbio’s Board as the Company progresses RTB101 into late-stage clinical development and gains additional insights on the potential benefits of TORC1 inhibition in other indications,” said Dr. Chodakewitz. “I look forward to working with the team to further advance our leadership in TORC1 inhibition and the treatment of aging-related diseases.”
resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines with the potential to extend healthy lifespan. resTORbio’s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems.
Forward Looking Statements:
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding our plans to develop and commercialize RTB101, including the therapeutic potential and clinical benefits thereof, the potential benefits of TORC1 inhibition on aging-related diseases, and our planned clinical trials for RTB101, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the delay of any planned clinical trials and/or development of RTB101; our ability to successfully demonstrate the efficacy and safety of our lead product candidate; the clinical results for our lead product candidate which may not support further development of additional indications; and obtaining, maintaining and protecting our intellectual property; as well as those risks more fully discussed in the section entitled “Risk Factors” in the Annual Report on Form 10-K filed by resTORbio, Inc. with the
Investor and Media Contact: